FDA批准首个用于诊断阿尔茨海默氏症的血液检测技术

Core Viewpoint - The FDA has approved the first blood test technology for diagnosing Alzheimer's disease, developed by Fujirebio Diagnostics, which is expected to accelerate diagnosis and improve access to treatment [1] Group 1: FDA Approval - The FDA approved Fujirebio Diagnostics' blood test technology "Lumipulse" for Alzheimer's disease diagnosis, marking it as the first approved blood testing device for this condition [1] - This approval signifies a shift towards less invasive and more accessible diagnostic methods compared to traditional approaches [1] Group 2: Comparison with Other Diagnostic Methods - Current diagnostic methods for Alzheimer's include invasive spinal taps to collect cerebrospinal fluid and expensive PET brain scans, which may not be covered by health insurance [1] - The new blood test offers a less invasive alternative, potentially increasing the number of individuals who can be diagnosed and treated [1]